Jennifer L. Good - Sep 19, 2022 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: President & CEO, Director
Signature: /s/ Christopher Galletta, attorney-in-fact
Stock symbol: TRVI
Transactions as of: Sep 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 9/19/2022, 04:26 PM
Previous filing: Jul 1, 2022
Next filing: Feb 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Performance Stock Options (right to buy)	Award	$0	+32K	+25%	$0.00	160K	Sep 19, 2022	Common Stock	32K	$3.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 160,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 32,000 shares of common stock.

Content

Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 160,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 32,000 shares of common stock.